Accepted for Publication: September 8, 2012.
Published Online: January 7, 2013. doi:10.1001/jamainternmed.2013.1397
Author Contributions: All authors had full access to all the data in the study, and Dr Gross takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Gross, Chagpar, and Ma. Acquisition of data: Long. Analysis and interpretation of data: Long, Ross, Abu-Khalaf, Wang, Killelea, Gold, and Chagpar. Drafting of the manuscript: Gross and Long. Critical revision of the manuscript for important intellectual content: Ross, Abu-Khalaf, Wang, Killelea, Gold, Chagpar, and Ma. Statistical analysis: Gross, Long, Wang, and Ma. Obtained funding: Gross. Administrative, technical, and material support: Long and Killelea. Study supervision: Chagpar.
Conflict of Interest Disclosures: Drs Gross and Ross are members of a scientific advisory board for FAIR Health Inc. Drs Gross and Ross receive support from Medtronic Inc to develop and implement methods of clinical trial data sharing and patient-level meta-analyses. Dr Abu-Khalaf has received research funding from and has served as a consultant for Abraxis Oncology (currently Celgene), Merck, Novartis, Glaxo-Smith-Kline, and Genentech/Roche.
Funding/Support: This study was supported by the National Cancer Institute (5R01CA149045) and the P30 Cancer Center Support Grant (CCSG) at the Yale Comprehensive Cancer Center. Dr Ross is supported by the National Institute on Aging (grant No. K08 AG032886) and by the American Federation for Aging Research through the Paul B. Beeson Career Development Award Program, by the Centers of Medicare and Medicaid Services (CMS) to develop and maintain performance measures that are used for public reporting, and by the Pew Charitable Trusts to examine regulatory issues at the US Food and Drug Administration. The collection of the California cancer incidence data used in this study was supported by the California Department of Public Health as part of the statewide cancer reporting program mandated by California Health and Safety Code Section 103885; the National Cancer Institute's SEER Program under contract N01-PC-35136 awarded to the Northern California Cancer Center, contract N01-PC-35139 awarded to the University of Southern California, and contract N02-PC-15105 awarded to the Public Health Institute; and the Centers for Disease Control and Prevention's (CDC’s) National Program of Cancer Registries, under agreement No. U55/CCR921930-02 awarded to the Public Health Institute.
Role of the Sponsor: The sponsors had no role in the design and conduct of the study; in the collection, analysis, and interpretation of the data; or in the preparation, review, or approval of the manuscript.
Disclaimer: The authors assume full responsibility for the accuracy and completeness of the ideas presented and the interpretation and reporting of the SEER-Medicare data. The ideas and opinions expressed herein are those of the author(s), and endorsement by the State of California, Department of Public Health, the National Cancer Institute, and the CDC or their contractors and subcontractors is not intended nor should be inferred.
Additional Contributions: We thank Edward Dostaler, BS, for his assistance in the preparation of this manuscript. We acknowledge the efforts of the Applied Research Program, NCI; the Office of Research, Development and Information, CMS; Information Management Services (IMS) Inc; and the SEER Program tumor registries in the creation of the SEER-Medicare database.